Kobo Biotech Share Price Today

Kobo Biotech shareholders approve FY24 accounts at 31st AGM

Kobo Biotech Limited concluded its 31st Annual General Meeting on July 24, 2026, where shareholders approved the annual accounts for the financial year ended March 31, 2024. The resolution received unanimous support from 17,934 votes cast by non-institutional public investors, while promoter and institutional groups did not participate in the voting process.

Kobo Biotech loss widens to ₹5.23 crore in FY25

Kobo Biotech Limited reported a net loss of ₹5.23 crore for FY25, widening from ₹4.93 crore in the previous year, with no revenue from operations. The CIRP remains in effect, and the Resolution Plan by Beaufond Industries Limited was approved by NCLT.

Kobo Biotech narrows net loss to ₹49.29 lakh in FY 2023-24

Kobo Biotech Limited reported a narrowed net loss of ₹49.29 lakh for FY 2023-24 compared to ₹55.53 lakh in the previous year, with zero revenue from operations due to suspended manufacturing activities. The company is currently under the Corporate Insolvency Resolution Process, with the Board's powers suspended and vested with the Resolution Professional.

NCLT Approves Beaufond Industries' Resolution Plan for Kobo Biotech Limited

The NCLT Hyderabad Bench approved the resolution plan of Beaufond Industries Limited for Kobo Biotech Limited on May 11, 2026, with a total resolution amount of INR 70.11 crores. Financial creditors are to receive INR 67.78 crores as part of the upfront payment, along with an equity upside of approximately 3% of total shareholding. The approved composite scheme involves amalgamation and demerger, resulting in a post-resolution total share capital of 3,93,47,700 shares at a face value of Rs. 10 each, with promoter shareholding at 57.23%. All pre-existing liabilities of the Corporate Debtor shall stand extinguished upon implementation of the plan.

Kobo Biotech Limited Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026

Kobo Biotech Limited filed its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, with BSE Limited on April 15, 2026. The certificate, submitted by Resolution Professional IP Namrata Amol Randeri, was supported by confirmation from registrar XL Softech Systems Ltd. regarding proper dematerialization processes and compliance with regulatory requirements during the quarter.

Kobo Biotech Limited Confirms Non-Large Corporate Status Under SEBI Framework

Kobo Biotech Limited has confirmed to BSE Limited that it does not qualify as a Large Corporate under SEBI's regulatory framework as of March 31, 2026. The confirmation references SEBI circulars SEBI/HO/DDHS/CIR/P/2018/144 and SEBI/HO/DDHS/P/CIR/2021/613 regarding debt securities issuance by large entities. The communication was signed by Resolution Professional IP Namrata Amol Randeri, indicating the company is under corporate insolvency resolution process.